Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
1985-10-16
|
| pubmed:abstractText |
Purified recombinant human interleukin 2 (RIL 2) derived from E. coli containing the inserted gene encoding for IL 2 was administered to 20 patients with a variety of malignancies. Toxicity was dose related and included fever, chills, malaise, arthralgias, myalgias, and unexpectedly, weight gain related to marked fluid retention. All patients receiving more than 10(5) U/kg total cumulative dose developed evidence of fluid retention, and all patients requiring discontinuance of RIL 2 (11/20) received total doses of between 2.54 X 10(5) U/kg to 15.4 X 10(5) U/kg. The limiting dose with this preparation was 3000 U/kg/hr by continuous administration or 10(6) U/kg by bolus administration. IL 2 was rapidly cleared from the plasma, with a half life of 6.9 min, and a later delayed clearance was consistent with a two-compartment model, with slower release from the extravascular space back into the plasma compartment. A marked change in lymphoid cells in the periphery was noted with an early depletion of all lymphoid cells, followed by an expansion of such cells with continuous IL 2 administration. A twofold to 16-fold expansion of total lymphoid cells in the peripheral blood could be demonstrated. TAC+ cells representing up to 25% of the circulating peripheral blood mononuclear cells could be demonstrated with 3 wk of continuous RIL 2 administration. Interferon-gamma levels increased in patients treated with IL 2. Precursors of lymphokine-activated killer cells generated under standard conditions were depleted within 2 to 3 min after IL 2 administration, but repopulated the peripheral blood after 7 to 10 days of continuous IL 2 administration. No tumor regression was seen in any of the cancer patients treated with IL 2 alone.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0022-1767
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
135
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2865-75
|
| pubmed:dateRevised |
2008-11-21
|
| pubmed:meshHeading |
pubmed-meshheading:2993418-Adrenocorticotropic Hormone,
pubmed-meshheading:2993418-Adult,
pubmed-meshheading:2993418-Aged,
pubmed-meshheading:2993418-Female,
pubmed-meshheading:2993418-Half-Life,
pubmed-meshheading:2993418-Humans,
pubmed-meshheading:2993418-Hydrocortisone,
pubmed-meshheading:2993418-Infusions, Parenteral,
pubmed-meshheading:2993418-Interferon-gamma,
pubmed-meshheading:2993418-Interleukin-2,
pubmed-meshheading:2993418-Killer Cells, Natural,
pubmed-meshheading:2993418-Leukocyte Count,
pubmed-meshheading:2993418-Lymphocyte Activation,
pubmed-meshheading:2993418-Lymphocytes,
pubmed-meshheading:2993418-Male,
pubmed-meshheading:2993418-Middle Aged,
pubmed-meshheading:2993418-Stem Cells,
pubmed-meshheading:2993418-T-Lymphocytes
|
| pubmed:year |
1985
|
| pubmed:articleTitle |
In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.
|
| pubmed:publicationType |
Journal Article
|